The CJC-1295 + Ipamorelin blend became the most widely used injectable GH secretagogue protocol not because it’s exotic, but because the logic is straightforward: two compounds, two separate receptor arms, one injection. If you’re going to run CJC-1295 and Ipamorelintogether anyway — and most people who use either will eventually use both — the pre-blended vial saves you a vial, a calculation, and an injection every time you dose.
What it is
The blend is a single vial containing CJC-1295 no-DAC (Modified GRF 1-29) and Ipamorelin at a fixed manufacturer ratio. CJC-1295 is a GHRH-receptor agonist — it triggers a GH pulse from the pituitary via the hypothalamic arm. Ipamorelin is a ghrelin-receptor agonist (GHS-R1a) — it adds a second stimulus to the same pulse via the ghrelin arm. Activating both receptor arms simultaneously produces a substantially larger pulse than either compound alone.
The no-DAC form of CJC-1295 is the right choice for a blend. With-DAC CJC-1295 is designed for once-weekly injections at an 8-day half-life — a poor fit for a timing-dependent blend. No-DAC has a half-life of roughly 15–30 minutes, producing a sharp, timed pulse that aligns with pre-bed and pre-workout windows. Most vendors produce a 10 mg vial at or near a 1:1 ratio; ratios vary and are not always disclosed. Check the certificate of analysis for the per-compound breakdown.
What the research actually shows
There is no direct clinical research on the pre-blended product. The blend is a combination of two well-characterized compounds — and each has its own evidence base. CJC-1295’s mechanism (GHRH-receptor agonism driving pulsatile GH secretion) is well-established. Ipamorelin’s selectivity (GH release without prolactin or cortisol elevation) is also well-characterized. The dual-receptor argument is mechanistically sound and accepted across the GH secretagogue literature.
What is not proven for the blend specifically: that a fixed-ratio vial produces the same GH output as independently titrated doses. The blend gives you the combination; it does not give you independent control. For the full evidence picture, the CJC-1295 post and the Ipamorelin post cover each component honestly.
How people dose it
Standard reconstitution: 10 mg vial + 2 mL bacteriostatic water = 5 mg/mL combined. Injection is subcutaneous, fasted.
- Low:100–150 mcg per injection (2–3 units on a U-100 syringe), once daily
- Medium:200–250 mcg per injection (4–5 units), once or twice daily
- High: 300 mcg per injection (6 units), two to three times daily
The high-dose ceiling of 300 mcg per injection follows the transcript ceiling for both component peptides individually (150–300 mcg subcutaneously, up to three times daily). That ceiling reflects the pituitary’s rate limit, not an arbitrary cap: beyond roughly 150 mcg per injection, you are approaching the saturation dose for the ghrelin receptor. More per injection does not mean proportionally more GH — more well-timed injections do. For the reconstitution math on your vial, use the blend calculator.
Timing rules are identical to the standalone compounds. Fasted injection is non-negotiable: food raises insulin, insulin raises somatostatin, and somatostatin directly opposes the GH-releasing signal both compounds are trying to amplify. Pre-bed (amplifies the natural nocturnal GH peak) and pre-workout (exercise compounds the GH pulse) are the two best windows. Monitor fasted blood glucose weekly while running any GH secretagogue; Berberine (500–2,000 mg/day) is the preferred glucose management tool because — unlike Metformin — it does not meaningfully suppress IGF-1.
What it stacks well with
The blend IS the canonical stack — there is no further combination with standalone CJC-1295 or standalone Ipamorelin that makes sense. Meaningful additions operate on separate axes: exogenous HGH layered on top (the secretagogue maintains pulsatile endogenous signaling; HGH provides a sustained baseline), or healing peptides like BPC-157 and TB-500 for users managing injury alongside body composition. Neither creates receptor overlap with the blend.
If you want to titrate the components independently — or explore the with-DAC CJC option the blend cannot deliver — read the CJC-1295 post and the Ipamorelin post for the full component-level protocols.
The honest caveats
- Fixed ratio = no independent titration. If water retention from the CJC component is a concern, or if you want more Ipamorelin for pulse amplitude without raising the CJC dose, the blend forces you to adjust both simultaneously. Separate vials solve this; the blend does not.
- Pituitary ceiling applies equally.For users over 35–40 whose GH output has declined, the ceiling from secretagogue stimulation is lower regardless of how well the compounds are combined. At that point, exogenous HGH becomes the more cost-effective tool.
- WADA prohibited and FDA Section 503a restricted. Both components are on the restricted compound list and on the WADA prohibited list. Standard workplace and military screens do not detect peptides; the risk is sport-specific.
- Vendor ratio transparency matters.A 10 mg vial labeled “CJC-1295 + Ipamorelin” could be anywhere from 3:7 to 7:3. Request the COA — the per-compound breakdown determines what you’re actually injecting.
The bottom line
The CJC-1295 + Ipamorelin blend is the right choice for most people starting injectable GH secretagogues precisely because it removes the complexity of managing two vials while delivering the dual-receptor coverage that makes the combination worth running in the first place. The math is straightforward, the protocol is well-established, and the compound tolerance profile is as clean as this drug class gets.
Use the CJC-1295 + Ipamorelin reconstitution calculator for the dose math. For the full secretagogue landscape — where this blend sits relative to Tesamorelin, Sermorelin, and exogenous HGH — read the GH secretagogues post. For protocol context and timing frameworks, the free Peptide Guide has it all.